Skip to main content

Strong associations between chromosomal aberrations in blood lymphocytes and the risk of urothelial and squamous cell carcinoma of the bladder

Research Abstract
Chromosomal aberrations (CAs) in blood lymphocytes have been shown to be associated with overall cancer risk and aging. However, their relationship to bladder cancer risk remains to be elucidated. In a case-control study of bladder cancer in Egypt, we examined the relationship between the increased frequency of CAs in blood lymphocytes and bladder cancer risk. High frequency of CAs was significantly associated with an increased risk of bladder cancer [adjusted odds ratios (OR) = 3.90, 95% confidence interval (CI) = 2.65–5.73]. The associations were somewhat stronger in squamous cell carcinomas (SCC, OR = 4.90) than in urothelial carcinomas (UC, OR = 3.62). We also identified chromosome specific CAs for chromosomes 3, 4, 5, 8, 9, 10, 11, 12, 17, 19 that were significantly associated with an increased risk of bladder cancer. We observed particularly strong associations between aberrations of chromosomes 12, 13, 17 and risk of SCC (OR = 7.06, 6.91 and 6.23, respectively). Conclusion: increased frequency of chromosomal aberrations in blood lymphocytes was significantly associated with bladder cancer risk. Overall and chromosome specific aberrations in blood lymphocytes may be a unique set of biomarkers for risk assessments of SCC and UC.
Research Authors
Hongkun Wang, Ying Wang, Krishna K. Kota, Bing Sun, Bhaskar Kallakury, Nabiel N. Mikhail, Douaa Sayed, Ahmed Mokhtar, Doaa Maximous, Etemad H. Yassin, Scarlett X. Sun, Xiaofei Chen, Christopher A. Loffredo & Yun-Ling Zheng
Research Department
Research Journal
Scientific Reports
Research Member
Douaa Mohamed Sayed Hussein
Research Pages
1-10
Research Publisher
NULL
Research Rank
1
Research Vol
Volume 7, Article number: 13493
Research Website
13493 | DOI:10.1038/s41598-017-13976-y
Research Year
2017

Strong associations between chromosomal aberrations in blood lymphocytes and the risk of urothelial and squamous cell carcinoma of the bladder

Research Abstract
Chromosomal aberrations (CAs) in blood lymphocytes have been shown to be associated with overall cancer risk and aging. However, their relationship to bladder cancer risk remains to be elucidated. In a case-control study of bladder cancer in Egypt, we examined the relationship between the increased frequency of CAs in blood lymphocytes and bladder cancer risk. High frequency of CAs was significantly associated with an increased risk of bladder cancer [adjusted odds ratios (OR) = 3.90, 95% confidence interval (CI) = 2.65–5.73]. The associations were somewhat stronger in squamous cell carcinomas (SCC, OR = 4.90) than in urothelial carcinomas (UC, OR = 3.62). We also identified chromosome specific CAs for chromosomes 3, 4, 5, 8, 9, 10, 11, 12, 17, 19 that were significantly associated with an increased risk of bladder cancer. We observed particularly strong associations between aberrations of chromosomes 12, 13, 17 and risk of SCC (OR = 7.06, 6.91 and 6.23, respectively). Conclusion: increased frequency of chromosomal aberrations in blood lymphocytes was significantly associated with bladder cancer risk. Overall and chromosome specific aberrations in blood lymphocytes may be a unique set of biomarkers for risk assessments of SCC and UC.
Research Authors
Hongkun Wang, Ying Wang, Krishna K. Kota, Bing Sun, Bhaskar Kallakury, Nabiel N. Mikhail, Douaa Sayed, Ahmed Mokhtar, Doaa Maximous, Etemad H. Yassin, Scarlett X. Sun, Xiaofei Chen, Christopher A. Loffredo & Yun-Ling Zheng
Research Journal
Scientific Reports
Research Member
Nabiel Nazmi Hanna Mikhail
Research Pages
1-10
Research Publisher
NULL
Research Rank
1
Research Vol
Volume 7, Article number: 13493
Research Website
13493 | DOI:10.1038/s41598-017-13976-y
Research Year
2017

New Look on Ureterocolic Diversion with Adjuvant Radiotherapy; SECI (South Egypt Cancer Institute) Experience

Research Abstract
Background: Ureterosigmoidostomy was the first form of continent urinary diversion and had broad popularity during the first half of the 20th century. Primary enthusiasm was followed by disappointment when serious problems such as pyelonephritis, electrolyte imbalance, renal calculi and renal function deterioration become evident. In the 1950s these life threatening complications led to avoid this urinary diversion in favor of uretro-intestinal conduits. Objectives: Our aim was to evaluate our experience in ureterocolic shunt after radical cystectomy for bladder cancer. Methodology: This study was conducted in surgical oncology department, South Egypt cancer institute, Assiut university; in the period from January 2012 to January 2017 and including 115 patients (75 males & 40 females). Results: This is retrospective study including 115 patients (75 males & 40 females). Operative time was 130 minutes ranging between 2 to 2.5 hours. Average blood loss was 450 ml. After removal of rectal tube all patients were continent except 15 patients who were improved after 1 - 3 days. Within a month 12 patients had night incontinence and 5 patients had day time incontinence. After that day and night continence gradually improved in all patients except two females who had persistent night soiling and was in need for night time rectal tube. Conclusion: Ureterosigmoidostomy regains the interest of surgical oncology and urologist because of its simplicity and absence of appliance as many patients refusing cutaneous stoma and others are not suitable for orthotopic substitutes.
Research Authors
Badawy M. Ahmed, Ebrahim Aboeleuon, Ahmed M. Abdel-Rahim, Osama M. Abd Elbadee
Research Journal
Journal of Cancer Therapy
Research Pages
898-906
Research Publisher
Scientific Research Publishing
Research Rank
1
Research Vol
9
Research Website
ISSN Online: 2151-1942
Research Year
2018

New Look on Ureterocolic Diversion with Adjuvant Radiotherapy; SECI (South Egypt Cancer Institute) Experience

Research Abstract
Background: Ureterosigmoidostomy was the first form of continent urinary diversion and had broad popularity during the first half of the 20th century. Primary enthusiasm was followed by disappointment when serious problems such as pyelonephritis, electrolyte imbalance, renal calculi and renal function deterioration become evident. In the 1950s these life threatening complications led to avoid this urinary diversion in favor of uretro-intestinal conduits. Objectives: Our aim was to evaluate our experience in ureterocolic shunt after radical cystectomy for bladder cancer. Methodology: This study was conducted in surgical oncology department, South Egypt cancer institute, Assiut university; in the period from January 2012 to January 2017 and including 115 patients (75 males & 40 females). Results: This is retrospective study including 115 patients (75 males & 40 females). Operative time was 130 minutes ranging between 2 to 2.5 hours. Average blood loss was 450 ml. After removal of rectal tube all patients were continent except 15 patients who were improved after 1 - 3 days. Within a month 12 patients had night incontinence and 5 patients had day time incontinence. After that day and night continence gradually improved in all patients except two females who had persistent night soiling and was in need for night time rectal tube. Conclusion: Ureterosigmoidostomy regains the interest of surgical oncology and urologist because of its simplicity and absence of appliance as many patients refusing cutaneous stoma and others are not suitable for orthotopic substitutes.
Research Authors
Badawy M. Ahmed, Ebrahim Aboeleuon, Ahmed M. Abdel-Rahim, Osama M. Abd Elbadee
Research Department
Research Journal
Journal of Cancer Therapy
Research Pages
898-906
Research Publisher
Scientific Research Publishing
Research Rank
1
Research Vol
9
Research Website
ISSN Online: 2151-1942
Research Year
2018

New Look on Ureterocolic Diversion with Adjuvant Radiotherapy; SECI (South Egypt Cancer Institute) Experience

Research Abstract
Background: Ureterosigmoidostomy was the first form of continent urinary diversion and had broad popularity during the first half of the 20th century. Primary enthusiasm was followed by disappointment when serious problems such as pyelonephritis, electrolyte imbalance, renal calculi and renal function deterioration become evident. In the 1950s these life threatening complications led to avoid this urinary diversion in favor of uretro-intestinal conduits. Objectives: Our aim was to evaluate our experience in ureterocolic shunt after radical cystectomy for bladder cancer. Methodology: This study was conducted in surgical oncology department, South Egypt cancer institute, Assiut university; in the period from January 2012 to January 2017 and including 115 patients (75 males & 40 females). Results: This is retrospective study including 115 patients (75 males & 40 females). Operative time was 130 minutes ranging between 2 to 2.5 hours. Average blood loss was 450 ml. After removal of rectal tube all patients were continent except 15 patients who were improved after 1 - 3 days. Within a month 12 patients had night incontinence and 5 patients had day time incontinence. After that day and night continence gradually improved in all patients except two females who had persistent night soiling and was in need for night time rectal tube. Conclusion: Ureterosigmoidostomy regains the interest of surgical oncology and urologist because of its simplicity and absence of appliance as many patients refusing cutaneous stoma and others are not suitable for orthotopic substitutes.
Research Authors
Badawy M. Ahmed, Ebrahim Aboeleuon, Ahmed M. Abdel-Rahim, Osama M. Abd Elbadee
Research Department
Research Journal
Journal of Cancer Therapy
Research Pages
898-906
Research Publisher
Scientific Research Publishing
Research Rank
1
Research Vol
9
Research Website
ISSN Online: 2151-1942
Research Year
2018

New Look on Ureterocolic Diversion with Adjuvant Radiotherapy; SECI (South Egypt Cancer Institute) Experience

Research Abstract
Background: Ureterosigmoidostomy was the first form of continent urinary diversion and had broad popularity during the first half of the 20th century. Primary enthusiasm was followed by disappointment when serious problems such as pyelonephritis, electrolyte imbalance, renal calculi and renal function deterioration become evident. In the 1950s these life threatening complications led to avoid this urinary diversion in favor of uretro-intestinal conduits. Objectives: Our aim was to evaluate our experience in ureterocolic shunt after radical cystectomy for bladder cancer. Methodology: This study was conducted in surgical oncology department, South Egypt cancer institute, Assiut university; in the period from January 2012 to January 2017 and including 115 patients (75 males & 40 females). Results: This is retrospective study including 115 patients (75 males & 40 females). Operative time was 130 minutes ranging between 2 to 2.5 hours. Average blood loss was 450 ml. After removal of rectal tube all patients were continent except 15 patients who were improved after 1 - 3 days. Within a month 12 patients had night incontinence and 5 patients had day time incontinence. After that day and night continence gradually improved in all patients except two females who had persistent night soiling and was in need for night time rectal tube. Conclusion: Ureterosigmoidostomy regains the interest of surgical oncology and urologist because of its simplicity and absence of appliance as many patients refusing cutaneous stoma and others are not suitable for orthotopic substitutes.
Research Authors
Badawy M. Ahmed, Ebrahim Aboeleuon, Ahmed M. Abdel-Rahim, Osama M. Abd Elbadee
Research Department
Research Journal
Journal of Cancer Therapy
Research Pages
898-906
Research Publisher
Scientific Research Publishing
Research Rank
1
Research Vol
9
Research Website
ISSN Online: 2151-1942
Research Year
2018

Bacillus Calmette-Guérin versus Gemcitabine for Intravesical Therapy in Intermediate and High-Risk Superficial Bladder Cancer

Research Abstract
Bacillus Calmette Guerin (BCG) has been the mainstay of intravesical treatment, however, its clinical effectiveness is accompanied by a wide range of adverse events. Gemcitabine has a good safety profile with promising features for the use against intermediate risk non-muscle invasive bladder cancer (NMIBC). It can be a potential chemotherapeutic drug for high- risk patients. The aim of this study was to evaluate the safety and efficacy of adjuvant intravesical gemcitabine versus BCG in the treatment of intermediate and high -risk NMIBC. Patients and methods: Between May 2006 and April 2008, a total of 57 patients were randomized into 2 groups; group I: 28 patients, were treated with six weekly intravesical instillation of BCG and group II: 29 patients, received six weekly intravesical grmcitabine. Patients were evaluated for response, at 8 weeks, then every 3 months. Outcome measures were response rate, overall recurrence rate, progression rate, median recurrence free period, median progression free period and 1-year recurrence free survival. Treatment related complications were also evaluated. Results: For intermediate risk patients, there was no significant difference between the two groups in the complete response (CR) rate (93.3% vs. 87.5%), the overall recurrence rate (33.3%vs.25%), the progression rate (6.7% vs. 6.2%), and the median progression free period (13 vs. 16 months). However, the median recurrence free period was longer for group I compared to group II (18.5 vs. 15 months) and the difference was statistically significant. Kaplan-Meier curve showed that there was no significant difference between the two groups in the 1-year recurrence free survival (95.3% vs. 98.7%) and the median recurrence free survival (22 vs.18 months). For high risk patients there was no significant difference between the 2groups in CR rate (61.5% vs. 76.9%), the progression rate (15.4% for both groups) the median recurrence free period (15 vs. 14 months) and the median progression free period (17 vs. 15 months). However, the overall recurrence rate of group I was lower than that of group II (7.7% vs. 30.8%) and the difference was statistically significant. Kaplan-Meier curve showed that there was no significant difference between the two groups in the 1-year recurrence free survival (76.9% vs. 69.2%) and the median recurrence free survival (18 vs.15 months). The adverse events of group I were more marked than that of group II. Conclusion: Gemcitabine is active and well tolerated for intravesical instillation.It is considered to be an efficient treatment for intermediate risk NMIBC. However, for high- risk group, it is inferior to BCG, but owing to its favorable toxicity profile, it may be useful for patients intolerant to BCG. [
Research Authors
Ahmed M. Abd-Alrahim and Hoda H. Essa
Research Journal
Journal of American Science, 2011;
Research Pages
416- 426
Research Publisher
NULL
Research Rank
1
Research Vol
7(8)
Research Website
ISSN: 1545-100)
Research Year
2011

Bacillus Calmette-Guérin versus Gemcitabine for Intravesical Therapy in Intermediate and High-Risk Superficial Bladder Cancer

Research Abstract
Bacillus Calmette Guerin (BCG) has been the mainstay of intravesical treatment, however, its clinical effectiveness is accompanied by a wide range of adverse events. Gemcitabine has a good safety profile with promising features for the use against intermediate risk non-muscle invasive bladder cancer (NMIBC). It can be a potential chemotherapeutic drug for high- risk patients. The aim of this study was to evaluate the safety and efficacy of adjuvant intravesical gemcitabine versus BCG in the treatment of intermediate and high -risk NMIBC. Patients and methods: Between May 2006 and April 2008, a total of 57 patients were randomized into 2 groups; group I: 28 patients, were treated with six weekly intravesical instillation of BCG and group II: 29 patients, received six weekly intravesical grmcitabine. Patients were evaluated for response, at 8 weeks, then every 3 months. Outcome measures were response rate, overall recurrence rate, progression rate, median recurrence free period, median progression free period and 1-year recurrence free survival. Treatment related complications were also evaluated. Results: For intermediate risk patients, there was no significant difference between the two groups in the complete response (CR) rate (93.3% vs. 87.5%), the overall recurrence rate (33.3%vs.25%), the progression rate (6.7% vs. 6.2%), and the median progression free period (13 vs. 16 months). However, the median recurrence free period was longer for group I compared to group II (18.5 vs. 15 months) and the difference was statistically significant. Kaplan-Meier curve showed that there was no significant difference between the two groups in the 1-year recurrence free survival (95.3% vs. 98.7%) and the median recurrence free survival (22 vs.18 months). For high risk patients there was no significant difference between the 2groups in CR rate (61.5% vs. 76.9%), the progression rate (15.4% for both groups) the median recurrence free period (15 vs. 14 months) and the median progression free period (17 vs. 15 months). However, the overall recurrence rate of group I was lower than that of group II (7.7% vs. 30.8%) and the difference was statistically significant. Kaplan-Meier curve showed that there was no significant difference between the two groups in the 1-year recurrence free survival (76.9% vs. 69.2%) and the median recurrence free survival (18 vs.15 months). The adverse events of group I were more marked than that of group II. Conclusion: Gemcitabine is active and well tolerated for intravesical instillation.It is considered to be an efficient treatment for intermediate risk NMIBC. However, for high- risk group, it is inferior to BCG, but owing to its favorable toxicity profile, it may be useful for patients intolerant to BCG. [
Research Authors
Ahmed M. Abd-Alrahim and Hoda H. Essa
Research Department
Research Journal
Journal of American Science, 2011;
Research Pages
416- 426
Research Publisher
NULL
Research Rank
1
Research Vol
7(8)
Research Website
ISSN: 1545-100)
Research Year
2011

Adjuvant intravesical instillation for primary intermediate and high-risk non-muscle invasive bladder cancer: BCG versus docetaxel.

Research Abstract
Background: BCG is the standard treatment for non-muscle invasive bladder cancer (NMIBC). However, the high recurrence rates and the significant local and systemic toxicity have led to increased interest in alternative intravesical therapies. Docetaxel has been shown to be a safe and effective intravesical therapy with no systemic absorption and minimal toxicity. Objectives: To compare the efficacy and safety of intravesical BCG and docetaxel for intermediate and high-risk NMIBC. Patients and methods: 82 patients with NMIBC were randomized into 2 groups; and treated with six weekly intravesical BCG (group I, 40 patients) and docetaxel (group II, 42 patients). Outcome measures were overall recurrence rate, progression rate, 1-year recurrence free and progression free survival. Treatment related toxicities were also evaluated. Results: No difference between the 2 groups in recurrence rate (32.5% vs. 42.9%), progression rate (20% vs. 28.6%), 1-year recurrence free survival (72.5% vs. 61.9%), 1-year progression free survival (80% vs.71.4%). No difference for intermediate and high risk patients in BCG group and their counterparts of docetaxel group in recurrence rate (16.7% vs. 42.9%) and (39.3% vs. 42.9%), progression rate (16.7% vs. 14.3%) and (21.4% vs. 35.7%), 1-year recurrence free survival (83.3% vs. 76.9%) and (67.9% vs. 53.6%), 1-year progression free survival (83.3% vs. 84.6%) and (78.6% vs. 65.5). Age, grade and multiplicity were independent predictive factors for recurrence while grade was the independent factor for progression. The adverse events of BCG group were more marked. Conclusions: Intravesical docetaxel demonstrate significant efficacy and minimal toxicity for the management of NMIBC. In comparison to BCG, there was no significant difference in terms of disease recurrence, progression or survival, and the decision to use either agent may be based on adverse events and cost. The results of this study support the role of intravesical docetaxel for intermediate risk patients and it can be of major concern for high risk patients, however, randomized multi-institutional trials should be considered.
Research Authors
Hoda H. Essa and Ahmed M. Abd-Alrahim
Research Department
Research Journal
Annals of Cancer Research
Research Pages
1-8
Research Publisher
NULL
Research Rank
1
Research Vol
3:4
Research Website
ISSN 2058-7775
Research Year
2016

Adjuvant intravesical instillation for primary intermediate and high-risk non-muscle invasive bladder cancer: BCG versus docetaxel.

Research Abstract
Background: BCG is the standard treatment for non-muscle invasive bladder cancer (NMIBC). However, the high recurrence rates and the significant local and systemic toxicity have led to increased interest in alternative intravesical therapies. Docetaxel has been shown to be a safe and effective intravesical therapy with no systemic absorption and minimal toxicity. Objectives: To compare the efficacy and safety of intravesical BCG and docetaxel for intermediate and high-risk NMIBC. Patients and methods: 82 patients with NMIBC were randomized into 2 groups; and treated with six weekly intravesical BCG (group I, 40 patients) and docetaxel (group II, 42 patients). Outcome measures were overall recurrence rate, progression rate, 1-year recurrence free and progression free survival. Treatment related toxicities were also evaluated. Results: No difference between the 2 groups in recurrence rate (32.5% vs. 42.9%), progression rate (20% vs. 28.6%), 1-year recurrence free survival (72.5% vs. 61.9%), 1-year progression free survival (80% vs.71.4%). No difference for intermediate and high risk patients in BCG group and their counterparts of docetaxel group in recurrence rate (16.7% vs. 42.9%) and (39.3% vs. 42.9%), progression rate (16.7% vs. 14.3%) and (21.4% vs. 35.7%), 1-year recurrence free survival (83.3% vs. 76.9%) and (67.9% vs. 53.6%), 1-year progression free survival (83.3% vs. 84.6%) and (78.6% vs. 65.5). Age, grade and multiplicity were independent predictive factors for recurrence while grade was the independent factor for progression. The adverse events of BCG group were more marked. Conclusions: Intravesical docetaxel demonstrate significant efficacy and minimal toxicity for the management of NMIBC. In comparison to BCG, there was no significant difference in terms of disease recurrence, progression or survival, and the decision to use either agent may be based on adverse events and cost. The results of this study support the role of intravesical docetaxel for intermediate risk patients and it can be of major concern for high risk patients, however, randomized multi-institutional trials should be considered.
Research Authors
Hoda H. Essa and Ahmed M. Abd-Alrahim
Research Journal
Annals of Cancer Research
Research Pages
1-8
Research Publisher
NULL
Research Rank
1
Research Vol
3:4
Research Website
ISSN 2058-7775
Research Year
2016
Subscribe to